ASCO 2015 - Chicago - CML - Chronic Myeloid Leukemia
GENERAL INFORMATION
ASCO American Society of Clinical Oncology - May 29 - June 2, 2015 - McCormick Place, Chicago, Illinois
ABSTRACTS ABOUT CML
Impact of unbalanced karyotypes at diagnosis on prognosis of CML.
Impact of nilotinib treatment on subclinical cardiovascular biomakers.
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.
Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.
Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Ph+) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure.
Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.
Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.
Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis.
Survival of BCR-ABL positive and negative chronic myeloid leukemia: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database.
CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.
Can curcumin induces selective packaging of miRNAs in exosomes? A pilot study in chronic myelogenous leukemia...
Modulation of lipid rafts (LR), p-glycoprotein (P-gp) and proinflammatory cytokines (PIC) with HMG-Co A reductase inhibitor simvastatin (SV) in chronic myelogenous leukemia (CML) patients with imatinib mesylate (IM) resistance.
Ethnic differences in survival of elderly chronic myeloid leukemia patients in pre- and post-imatinib era in the United States.
Vascular occlusive events (VOE) and mortality among elderly patients (pts) with chronic myeloid leukemia (CML): A retrospective analysis of linked SEER-Medicare data.
Population based testing and treatment characteristics for CML.
Treatment-adherence beliefs and behaviors in patients with chronic myeloid leukemia (CML).
Is the high cost of CML care "worth it"?
Evaluation of prevalence and cost burden of comorbidities among patients with chronic myeloid leukemia (CML) in the U.S.
Association of BCR-ABL mutation testing in patients with CML with likelihood of improvement in subsequent BCR-ABL test results.
Impact of unbalanced karyotypes at diagnosis on prognosis of CML.
Impact of nilotinib treatment on subclinical cardiovascular biomakers.
Four-year minimum follow-up of ongoing patients (pts) with chronic-phase chronic myeloid leukemia (CP-CML) in a phase 1 trial of ponatinib (PON).
Elevated blood pressure (BP) and adverse events (AEs) of hypertension (HTN) in ponatinib (PON) leukemia trials.
Efficacy and safety of ponatinib in heavily pretreated leukemia patients in the PACE trial: 3-year results.
Long-term bosutinib (BOS) for Philadelphia Chromosome–Positive (Ph+) advanced (ADV) chronic myeloid leukemia (CML) after prior tyrosine kinase inhibitor (TKI) failure.
Comparing the efficacy of generic Imatinib formulations with the original Imatinib as the frontline tyrosine kinase inhibitor in chronic phase chronic myeloid leukemia.
Patient characteristics and adverse events (AEs) of tyrosine kinase inhibitors (TKIs) for the treatment of chronic myeloid leukemia (CML) in real world settings.
Cardiovascular events in patients with chronic myelogenous leukemia treated with tyrosine kinase inhibitors: A systematic review and meta-analysis.
Survival of BCR-ABL positive and negative chronic myeloid leukemia: A propensity matched analysis of the Surveillance, Epidemiology, and End Results database.
CML leukemic stem cell (CML LSC): Its existence in patients who achieved cytogenetic/molecular response under treatment of TKI.
Can curcumin induces selective packaging of miRNAs in exosomes? A pilot study in chronic myelogenous leukemia...
Modulation of lipid rafts (LR), p-glycoprotein (P-gp) and proinflammatory cytokines (PIC) with HMG-Co A reductase inhibitor simvastatin (SV) in chronic myelogenous leukemia (CML) patients with imatinib mesylate (IM) resistance.
Ethnic differences in survival of elderly chronic myeloid leukemia patients in pre- and post-imatinib era in the United States.
Vascular occlusive events (VOE) and mortality among elderly patients (pts) with chronic myeloid leukemia (CML): A retrospective analysis of linked SEER-Medicare data.
Population based testing and treatment characteristics for CML.
Treatment-adherence beliefs and behaviors in patients with chronic myeloid leukemia (CML).
Is the high cost of CML care "worth it"?
Evaluation of prevalence and cost burden of comorbidities among patients with chronic myeloid leukemia (CML) in the U.S.
Association of BCR-ABL mutation testing in patients with CML with likelihood of improvement in subsequent BCR-ABL test results.
